방사선종양학

본문글자크기
  • [Radiother Oncol.] Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.

    서울의대 / 위찬우, 김일한*,박철기*

  • 출처
    Radiother Oncol.
  • 등재일
    2018 Nov
  • 저널이슈번호
    129(2):347-351. doi: 10.1016/j.radonc.2018.09.001. Epub 2018 Sep 17.
  • 내용

    바로가기  >

    Abstract
    BACKGROUND AND PURPOSE:
    A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study.

    MATERIALS AND METHODS:
    Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I-III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively.

    RESULTS:
    The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4 months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8-76.6), 19.2 (95% CI, 16.2-22.1), and 13.8 months (95% CI, 11.8-15.4) (P < .001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7-76.3), 21. (95% CI, 18.6-23.3), and 14.3 months (95% CI, 12.5-16.1) (P < .001 for all comparisons) for class I, II, and III, respectively.

    CONCLUSION:
    The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials.

     


    Author information

    Wee CW1, Kim IH2, Park CK3, Kim JW4, Dho YS4, Ohka F5, Aoki K5, Motomura K5, Natsume A5, Kim N6, Suh CO6, Chang JH7, Kim SH8, Cho WK9, Lim DH9, Nam DH10, Choi JW10, Kim IA1, Kim CY11, Oh YT12, Cho O12, Chung WK13, Kim SH14, Kim E15.
    1
    Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, South Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
    2
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: ihkim@snu.ac.kr.
    3
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: nsckpark@snu.ac.kr.
    4
    Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea.
    5
    Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan.
    6
    Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
    7
    Department of Neurosurgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
    8
    Department of Pathology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
    9
    Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
    10
    Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
    11
    Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea; Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
    12
    Department of Radiation Oncology, Ajou University Medical Center, Suwon, South Korea.
    13
    Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
    14
    Department of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea School of Medicine, Suwon, South Korea.
    15
    Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.

  • 키워드
    Glioblastoma; IDH1; MGMT; Recursive partitioning analysis; Validation
  • 덧글달기
    덧글달기
       IP : 3.226.254.255

    등록